Progesterone supplementation for HIV-positive pregnant women on protease inhibitor-based antiretroviral regimens (the ProSPAR study): a study protocol for a pilot randomized controlled trial

Kaitlin Siou, Sharon L Walmsley, Kellie E Murphy, Janet Raboud, Mona Loutfy, Mark H Yudin, Michael Silverman, Noor N Ladhani, Lena Serghides, Kaitlin Siou, Sharon L Walmsley, Kellie E Murphy, Janet Raboud, Mona Loutfy, Mark H Yudin, Michael Silverman, Noor N Ladhani, Lena Serghides

Abstract

Background: In Canada, the majority of HIV-positive pregnant women receive combination antiretroviral therapy that includes a ritonavir-boosted protease inhibitor to prevent mother-to-child HIV transmission. However, protease inhibitor-based combination antiretroviral therapy has been associated with increased rates of preterm, low birth weight, and small for gestational age births. Our previous experimental findings demonstrate that protease inhibitor use during pregnancy is associated with decreased progesterone levels that correlate with fetal growth, and that progesterone supplementation can improve protease inhibitor-induced fetal growth restriction. We hypothesize that HIV-positive pregnant women who receive protease inhibitor-based combination therapy may also benefit from progesterone supplementation during pregnancy.

Methods/design: In order to test this hypothesis, we have designed an open-label, multi-centre, randomized controlled (parallel group) pilot trial. The initial goal of this trial is to test feasibility and acceptability of our intervention. Forty HIV-positive pregnant women who are either on, or intending to start or switch to a boosted protease inhibitor-based combination antiretroviral regimen will be enrolled from six sites across Ontario, Canada. Twenty-five women will be randomized to self-administer natural progesterone (Prometrium, 200 mg) vaginally every night starting between gestational week 16 and 24 until week 36, and 15 women will be randomized to no intervention. While the participants and treating physicians will not be blinded, the laboratory personnel performing the biochemical and morphological evaluations will be blinded to ensure unbiased evaluation. The primary outcome of the pilot study is the feasibility of enrolment as measured by the recruitment rate and patient-reported reasons to decline participation. Secondary outcomes in participants include safety, acceptability, and adherence to progesterone supplementation.

Discussion: Given the safety of intravaginal progesterone and its current use in the general obstetrical population to prevent recurrent preterm delivery, this pilot study will provide data to determine the feasibility of a larger randomized controlled trial to assess the impact of this intervention on improving neonatal health in the context of HIV-positive pregnancies.

Trial registration: ClinicalTrials.gov, NCT02400021.

Keywords: Feasibility; HIV; Low birth weight; Pilot study; Pregnancy; Preterm birth; Progesterone supplementation; Protease inhibitors; RCT.

Figures

Fig. 1
Fig. 1
Schematic of study design

References

    1. INSIGHT START Study Group et al Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373(9):795–807. doi: 10.1056/NEJMoa1506816.
    1. Townsend CL, Cortina-Borja M, Peckham CS, de Ruiter A, Lyall H, Tookey PA. Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000-2006. AIDS. 2008;22(8):973–81. doi: 10.1097/QAD.0b013e3282f9b67a.
    1. Warszawski J, Tubiana R, Le Chenadec J, Blanche S, Teglas JP, Dollfus C, Faye A, Burgard M, Rouzioux C, Mandelbrot L. ANRS French Perinatal Cohort. Mother-to-child HIV transmission despite antiretroviral therapy in the ANRS French Perinatal Cohort. AIDS. 2008;22(2):289–99. doi: 10.1097/QAD.0b013e3282f3d63c.
    1. Word Health Organisation (WHO). Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. September 2015. Available at . Accessed January 2016.
    1. Panel on treatment of HIV-infected pregnant women and prevention of perinatal transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. Available at . Accessed 7 Feb 2014.
    1. Lorenzi P, Spicher VM, Laubereau B, Hirschel B, Kind C, Rudin C, Irion O, Kaiser L. Antiretroviral therapies in pregnancy: maternal, fetal and neonatal effects. Swiss HIV Cohort Study, the Swiss Collaborative HIV and Pregnancy Study, and the Swiss Neonatal HIV Study. AIDS. 1998;12(18):F241–7. doi: 10.1097/00002030-199818000-00002.
    1. European Collaborative Study; Swiss Mother and Child HIV Cohort Study Combination antiretroviral therapy and duration of pregnancy. AIDS. 2000;14(18):2913–20. doi: 10.1097/00002030-200012220-00013.
    1. European Collaborative Study Exposure to antiretroviral therapy in utero or early life: the health of uninfected children born to HIV-infected women. J Acquir Immune Defic Syndr. 2003;32(4):380–7. doi: 10.1097/00126334-200304010-00006.
    1. Thorne C, Patel D, Newell ML. Increased risk of adverse pregnancy outcomes in HIV- infected women treated with highly active antiretroviral therapy in Europe. AIDS. 2004;18(17):2337–9. doi: 10.1097/00002030-200411190-00019.
    1. Cotter AM, Garcia AG, Duthely ML, Luke B, O’Sullivan MJ. Is antiretroviral therapy during pregnancy associated with an increased risk of preterm delivery, low birth weight, or stillbirth? J Infect Dis. 2006;193(9):1195–201. doi: 10.1086/503045.
    1. Schulte J, Dominguez K, Sukalac T, Bohannon B, Pediatric Spectrum of HIV Disease Consortium. Fowler MG. Declines in low birth weight and preterm birth among infants who were born to HIV-infected women during an era of increased use of maternal antiretroviral drugs: pediatric spectrum of HIV disease, 1989-2004. Pediatrics. 2007;119(4):e900–6. doi: 10.1542/peds.2006-1123.
    1. Townsend CL, Cortina-Borja M, Peckham CS, Tookey PA. Antiretroviral therapy and premature delivery in diagnosed HIV-infected women in the United Kingdom and Ireland. AIDS. 2007;21(8):1019–26. doi: 10.1097/QAD.0b013e328133884b.
    1. Martin F, Taylor GP. Increased rates of preterm delivery are associated with the initiation of highly active antiretroviral therapy during pregnancy: a single-center cohort study. J Infect Dis. 2007;196(4):558–61. doi: 10.1086/519848.
    1. Tuomala RE, Shapiro DE, Mofenson LM, Bryson Y, Culnane M, Hughes MD, O’Sullivan MJ, Scott G, Stek AM, Wara D, Bulterys M. Antiretroviral therapy during pregnancy and the risk of an adverse outcome. N Engl J Med. 2002;346(24):1863–70. doi: 10.1056/NEJMoa991159.
    1. Szyld EG, Warley EM, Freimanis L, Gonin R, Cahn PE, Calvet GA, Duarte G, Melo VH, NISDI Perinatal Study Group. Read JS. Maternal antiretroviral drugs during pregnancy and infant low birth weight and preterm birth. AIDS. 2006;20(18):2345–53. doi: 10.1097/01.aids.0000253362.01696.9d.
    1. Kourtis AP, Schmid CH, Jamieson DJ, Lau J. Use of antiretroviral therapy in pregnant HIV-infected women and the risk of premature delivery: a meta-analysis. AIDS. 2007;21(5):607–15. doi: 10.1097/QAD.0b013e32802ef2f6.
    1. Thorne C, Fiore S, Rudin C. Antiretroviral therapy during pregnancy and the risk of an adverse outcome. N Engl J Med. 2003;348(5):471–2. doi: 10.1056/NEJM200301303480519.
    1. Tuomala RE, Yawetz S. Protease inhibitor use during pregnancy: is there an obstetrical risk? J Infect Dis. 2006;193(9):1191–4. doi: 10.1086/503049.
    1. Patel K, Shapiro DE, Brogly SB, Livingston EG, Stek AM, Bardeguez AD, Tuomala RE. P1025 team of the International Maternal Pediatric Adolescent AIDS Clinical Trials Group. Prenatal protease inhibitor use and risk of preterm birth among HIV-infected women initiating antiretroviral drugs during pregnancy. J Infect Dis. 2010;201(7):1035–44. doi: 10.1086/651232.
    1. Boer K, et al. The AmRo study: pregnancy outcome in HIV-1-infected women under effective highly active antiretroviral therapy and a policy of vaginal delivery. BJOG. 2007;114:148. doi: 10.1111/j.1471-0528.2006.01183.x.
    1. Habib NA, et al. Maternal HIV status and pregnancy outcomes in northeastern Tanzania: a registry-based study. BJOG. 2008;115:616. doi: 10.1111/j.1471-0528.2008.01672.x.
    1. Kowalska A, et al. Effect of antiretroviral therapy on pregnancy outcome in HIV-1 positive women. Med Wieku Rozwoj. 2003;7:459.
    1. Grosch-Woerner I, et al. Increased rate of prematurity associated with antenatal antiretroviral therapy in German/Austrian cohort of HIV-1 infected women. HIV Med. 2008;9:6. doi: 10.1111/j.1468-1293.2008.00520.x.
    1. Azria E, et al. Pregnancy outcomes in women with HIV type-1 receiving a lopinavir/ritonavir-containing regimen. Antivir Ther. 2009;14:423.
    1. Lorenzi P, et al. Antiretroviral therapies in pregnancy: maternal, fetal and neonatal effects. Swiss HIV Cohort Study, the Swiss Collaborative HIV and Pregnancy Study, and the Swiss Neonatal HIV Study. AIDS. 1998;12:F241. doi: 10.1097/00002030-199818000-00002.
    1. Machado ES, et al. Pregnancy outcome in women infected with HIV-1 receiving combination antiretroviral therapy before versus after conception. Sex Transm Infect. 2009;85:82. doi: 10.1136/sti.2008.032300.
    1. Chen JY, Ribaudo HJ, Souda S, Parekh N, Ogwu A, Lockman S, Powis K, Dryden- Peterson S, Creek T, Jimbo W, Madidimalo T, Makhema J, Essex M, Shapiro RL. Highly active antiretroviral therapy and adverse birth outcomes among HIV-infected women in Botswana. J Infect Dis. 2012;206(11):1695–705. doi: 10.1093/infdis/jis553.
    1. Ekouevi DK, Coffie PA, Becquet R, Tonwe-Gold B, Horo A, Thiebaut R, Leroy V, Blanche S, Dabis F, Abrams EJ. Antiretroviral therapy in pregnant women with advanced HIV disease and pregnancy outcomes in Abidjan. Côte d'Ivoire AIDS. 2008;22(14):1815–20. doi: 10.1097/QAD.0b013e32830b8ab9.
    1. Powis KM, Kitch D, Ogwu A, Hughes MD, Lockman S, Leidner J, van Widenfelt E, Moffat C, Moyo S, Makhema J, Essex M, Shapiro RL. Increased risk of preterm delivery among HIV-infected women randomized to protease versus nucleoside reverse transcriptase inhibitor-based HAART during pregnancy. J Infect Dis. 2011;204(4):506–14. doi: 10.1093/infdis/jir307.
    1. van Wassenaer A. Neurodevelopmental consequences of being born SGA. Pediatr Endocrinol Rev. 2005;2:372–7.
    1. Allen MC. Neurodevelopmental outcomes in preterm infants. Curr Opin Neurol. 2008;21:123–8. doi: 10.1097/WCO.0b013e3282f88bb4.
    1. Procianoy RS, et al. Neurodevelopmental outcomes of appropriate and small for gestational age very low birth weight infants. J Child Neurol. 2009;24:788–94. doi: 10.1177/0883073808331087.
    1. Sommerfel K, et al. Cognitive development of term small for gestational age children at five years of age. Arch Dis Child. 2000;83:25–30. doi: 10.1136/adc.83.1.25.
    1. Strauss RS, et al. Growth and development of term children born with low birth weight: effects of genetic and environmental factors. J Pediatr. 1998;133:67–72. doi: 10.1016/S0022-3476(98)70180-5.
    1. Figueras F, et al. Neurobehavior in term, small-for-gestational age infants with normal placental function. Pediatrics. 2009;124(5):e934–41. doi: 10.1542/peds.2008-3346.
    1. Barker DJP, et al. Trajectories of growth among children who have coronary events as adults. N Engl J Med. 2005;353:1802–9. doi: 10.1056/NEJMoa044160.
    1. Richards M, et al. Birth weight and cognitive function in the British 1946 birth cohort: longitudinal population based study. BMJ (Clinical research ed) 2001;322:199–203. doi: 10.1136/bmj.322.7280.199.
    1. Phillips DIW. Elevated plasma cortisol concentrations: a link between low birth weight and the insulin resistance syndrome? J Clin Endocrin Metab. 1998;83:757–60.
    1. Steffensen FH, et al. Low birth weight and preterm delivery as risk factors for asthma and atopic dermatitis in young adult males. Epidemiology. 2000;11:185–8. doi: 10.1097/00001648-200003000-00018.
    1. Papp E, et al. HIV protease inhibitor use during pregnancy is associated with decreased progesterone levels, suggesting a potential mechanism contributing to fetal growth restriction. J Infect Dis. 2015;211(1):10–8. doi: 10.1093/infdis/jiu393.
    1. Farine D, et al. The use of progesterone for prevention of preterm birth. SOGC Technical Update JOGC. 2008;202:67–71.
    1. U.S. Food and Drug Administration Press Release. FDA approves drug to reduce risk of preterm birth in at-risk pregnant women. Feb 4 2011;
    1. Dodd JM, Jones L, Flenady V, Cincotta R, Crowther CA. Prenatal administration of progesterone for preventing preterm birth in women considered to be at risk of preterm birth. Cochrane Database Syst Rev. 2013;7
    1. Sanchez-Ramos L, Kaunitz AM, Delke I. Progestational agents to prevent preterm birth: a meta-analysis of randomized controlled trials. Obstet Gynecol. 2005;105(2):273–9. doi: 10.1097/01.AOG.0000150559.59531.b2.
    1. Mackenzie R, Walker M, Armson A, Hannah ME. Progesterone for the prevention of preterm birth among women at increased risk: a systematic review and meta-analysis of randomized controlled trials. Am J Obstet Gynecol. 2006;194(5):1234–42. doi: 10.1016/j.ajog.2005.06.049.
    1. Rode L, Langhoff-Roos J, Andersson C, Dinesen J, Hammerum MS, Mohapeloa H, Tabor A. Systematic review of progesterone for the prevention of preterm birth in singleton pregnancies. Acta Obstet Gynecol Scand. 2009;88(11):1180–9. doi: 10.3109/00016340903280982.
    1. Su LL, Samuel M, Chong YS. Progestational agents for treating threatened or established preterm labour. Cochrane Database Syst Rev. 2014;1:CD006770.
    1. Division of AIDS National Institute of Allergy and Infectious Diseases. Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events. Version 2.0 November 2014. Available at . Accessed January 2016.
    1. Carmichael SL, et al. Maternal progestin intake and risk of hypospadias. Arch Pediatr Adolesc Med. 2005;159:957. doi: 10.1001/archpedi.159.10.957.
    1. Csapo AI, Pulkkinen M. Indispensability of the human corpus luteum in the maintenance of early pregnancy. Luteectomy evidence. Obstet Gynecol Surv. 1978;33:69–81. doi: 10.1097/00006254-197802000-00001.
    1. Peyron R, Aubény E, Targosz V, et al. Early termination of pregnancy with mifepristone (RU 486) and the orally active prostaglandin misoprostol. N Engl J Med. 1993;328:1509–13. doi: 10.1056/NEJM199305273282101.
    1. Mendelson CR. Minireview: fetal-maternal hormonal signaling in pregnancy and labor. Mol Endocrinol. 2009;23(7):947–54. doi: 10.1210/me.2009-0016.
    1. Pope Paul VI. Institute study, The Medical & Surgical Practice of NaProTechnology, Pope Paul VI Institute Press, Omaha. 2004.
    1. Lachelin GCL, et al. Low saliva progesterone concentrations are associated with spontaneous early preterm labour (before 34 weeks of gestation) in women at increased risk of preterm delivery. BJOG. 2009;116:1515. doi: 10.1111/j.1471-0528.2009.02293.x.
    1. Cousins LM, et al. Serum progesterone and estradiol-17beta levels in premature and term labor. Am J Obstet Gynecol. 1977;127:612. doi: 10.1016/0002-9378(77)90359-3.
    1. Salas SP, et al. Maternal plasma volume expansion and hormonal changes in women with idiopathic fetal growth restriction. Obstet Gynecol. 1993;81:1029.
    1. Johnson JW, Austin KL, Jones GS, et al. Efficacy of 17alpha-hydroxyprogesterone caproate in the prevention of premature labor. N Engl J Med. 1975;293:675–80. doi: 10.1056/NEJM197510022931401.
    1. Keirse MJ. Progestogen administration in pregnancy may prevent preterm delivery. Br J Obstet Gynaecol. 1990;97:149–54. doi: 10.1111/j.1471-0528.1990.tb01740.x.
    1. Hassan SS, Romero R, Vidyadhari D, for the PREGNANT Trial et al. Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol. 2011;38:18–31. doi: 10.1002/uog.9017.
    1. DeFranco EA, O’Brien JM, Adair CD, et al. Vaginal progesterone is associated with a decrease in risk for early preterm birth and improved neonatal outcome in women with a short cervix: a secondary analysis from a randomized, double- blind, placebo-controlled trial. Ultrasound Obstet Gynecol. 2007;30:697–705. doi: 10.1002/uog.5159.
    1. McKay LA et al. Re-analysis of the PREGNANT trial confirms that vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix. Ultrsound Obstet Gynecol 2014; ahead of print. PMID: 24585456
    1. Majhi P, et al. Intravaginal use of natural micronized progesterone to prevent pre-term birth: a randomised trial in Indian. J Obstet Gynaecol. 2009;29:493. doi: 10.1080/01443610902980878.
    1. O’Brien JM, Adair CD, Lewis DF, et al. Progesterone vaginal gel for the reduction of recurrent preterm birth: primary results from a ran- domized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol. 2007;30:687–96. doi: 10.1002/uog.5158.
    1. Romero R, et al. Vaginal progesterone in women with an asymptomatic sonographic short cervix in the midtrimester decreases preterm delivery and neonatal morbidity: a systematic review and metaanalysis of individual patient data. Am J Obstet Gynecol. 2012;206:124.e1–19. doi: 10.1016/j.ajog.2011.12.003.
    1. Medscape Reference. Progesterone intravaginal gel (Rx) – Crinone, Endometrin, Prochieve, Progesterone, Vaginal; Contraindications & Cautions. Available at . Accessed 11 Feb 2014.
    1. Vallejo M, et al. Potential role of trans-inhibition of the bile salt export pump by progesterone metabolites in the etiopathogenesis of intrahepatic cholestasis of pregnancy. J Hepatol. 2006;44:1150. doi: 10.1016/j.jhep.2005.09.017.
    1. Bacq Y, et al. Intrahepatic cholestasis of pregnancy: a French prospective study. Hepatology. 1997;26:358. doi: 10.1002/hep.510260216.
    1. Rebarber A, et al. Increased incidence of gestational diabetes in women receiving prophylactic 17 alpha-hydroxyprogesterone caproate for prevention of recurrent preterm delivery. Diabetes Care. 2007;30:2277. doi: 10.2337/dc07-0564.
    1. Norman JE, et al. Vaginal progesterone prophylaxis for preterm birth (the OPPTIMUM study): a multicentre, randomised, double-blind trial. Lancet. 2016;387:2106–16. doi: 10.1016/S0140-6736(16)00350-0.
    1. Archer DF, et al. Initial and steady-state pharmacokinetics of a vaginally administered formulation of progesterone. Am J Obstet Gynecol. 1995;173:471. doi: 10.1016/0002-9378(95)90268-6.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel